{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T21:14:50Z","timestamp":1784754890795,"version":"3.55.0"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), demonstrates significant efficacy in treating non-small cell lung cancer (NSCLC) harboring sensitive EGFR mutations. However, EGFR-TKI-induced interstitial lung disease (ILD) is a recognized and severe adverse reaction that can be fatal. Given the often limited patient acceptance of chemotherapy, there is currently no international consensus on the efficacy and safety of rechallenging with an EGFR-TKI following EGFR-TKI-induced ILD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Summary<\/jats:title>\n                    <jats:p>We report the case of a 73-year-old male with stage IV lung adenocarcinoma carrying an EGFR exon 19 deletions (Ex19del) mutation, who received first-line osimertinib at 80\u00a0mg daily. In the third month of treatment, the patient developed grade IV (CTCAE v5.0) ILD, presenting with dyspnea, chest tightness, dry cough, and fever. Arterial blood gas analysis indicated type I respiratory failure, and a chest CT scan revealed new bilateral patchy and reticular opacities. As high-flow nasal cannula oxygen failed to maintain adequate oxygen saturation, the patient was transferred to the intensive care unit (ICU), where he received endotracheal intubation, anti-inflammatory therapy with methylprednisolone, and anti-infective treatment. After 18 days, he recovered well and was discharged. Post-discharge, oral corticosteroid therapy was continued, and nintedanib was administered for its anti-fibrotic effects. The patient subsequently declined chemotherapy. Two months after corticosteroid therapy, EGFR-TKI treatment was rechallenged with aumolertinib at a reduced dose of 55\u00a0mg daily. After 1\u00a0month of treatment, the patient experienced no recurrence of dyspnea or other respiratory symptoms. A follow-up CT scan indicated resolution of the interstitial pneumonia and shrinkage of the pulmonary tumor. The aumolertinib dose was then increased to the standard 110\u00a0mg daily and treatment was continued.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Rechallenging with an EGFR-TKI after osimertinib-induced ILD remains highly challenging, particularly for grade 3 or higher ILD. In this case, following an adequate course of corticosteroid and anti-fibrotic therapy, successful rechallenge was achieved by initiating treatment with a low dose of aumolertinib, which was later escalated to the conventional dose.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1785616","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T07:49:35Z","timestamp":1776066575000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Report: A successful rechallenge with aumolertinib after osimertinib-induced severe interstitial lung disease"],"prefix":"10.3389","volume":"17","author":[{"given":"Hejing","family":"Bao","sequence":"first","affiliation":[{"name":"Department of Oncology, The Affiliated Panyu Center Hospital, Guangzhou Medical University","place":["Guangzhou, Guangdong, China"]},{"name":"Cancer Institute of Panyu District, The Affiliated Panyu Center Hospital, Guangzhou Medical University","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caijiu","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Affiliated Panyu Center Hospital, Guangzhou Medical University","place":["Guangzhou, Guangdong, China"]},{"name":"Cancer Institute of Panyu District, The Affiliated Panyu Center Hospital, Guangzhou Medical University","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Affiliated Panyu Center Hospital, Guangzhou Medical University","place":["Guangzhou, Guangdong, China"]},{"name":"Cancer Institute of Panyu District, The Affiliated Panyu Center Hospital, Guangzhou Medical University","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoran","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Affiliated Panyu Center Hospital, Guangzhou Medical University","place":["Guangzhou, Guangdong, China"]},{"name":"Cancer Institute of Panyu District, The Affiliated Panyu Center Hospital, Guangzhou Medical University","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hehong","family":"Bao","sequence":"additional","affiliation":[{"name":"Department of Psychosomatic Medicine, Chongqing University Three Gorges Hospital","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiazhu","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Affiliated Panyu Center Hospital, Guangzhou Medical University","place":["Guangzhou, Guangdong, China"]},{"name":"Cancer Institute of Panyu District, The Affiliated Panyu Center Hospital, Guangzhou Medical University","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Affiliated Panyu Center Hospital, Guangzhou Medical University","place":["Guangzhou, Guangdong, China"]},{"name":"Cancer Institute of Panyu District, The Affiliated Panyu Center Hospital, Guangzhou Medical University","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Affiliated Panyu Center Hospital, Guangzhou Medical University","place":["Guangzhou, Guangdong, China"]},{"name":"Cancer Institute of Panyu District, The Affiliated Panyu Center Hospital, Guangzhou Medical University","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1001\/jamaoncol.2020.6758","article-title":"Efficacy of osimertinib plus bevacizumab vs osimertinib in patients with EGFR T790M-Mutated non-small cell lung cancer previously treated with epidermal growth factor receptor-tyrosine kinase inhibitor: West Japan oncology group 8715L phase 2 randomized clinical trial","volume":"7","author":"Akamatsu","year":"2021","journal-title":"JAMA Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1038\/s41586-025-08586-y","article-title":"Clonal driver neoantigen loss under EGFR TKI and immune selection pressures","volume":"639","author":"Al Bakir","year":"2025","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1097\/CAD.0000000000001436","article-title":"Successful administration of low-dose almonertinib in a patient with lung adenocarcinoma after osimertinib-induced interstitial lung disease: a case report and literature review","volume":"34","author":"Chen","year":"2023","journal-title":"Anticancer Drugs"},{"key":"B4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3779\/j.issn.1009-3419.2019.02.01","article-title":"Chinese anti-cancer association","volume":"22","year":"2019","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"B5","doi-asserted-by":"publisher","first-page":"102664","DOI":"10.1016\/j.ctrv.2023.102664","article-title":"The role of anti-EGFR therapies in EGFR-TKI-resistant advanced non-small cell lung cancer","volume":"122","author":"Ciardiello","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"15027","DOI":"10.3390\/ijms232315027","article-title":"Pathological roles of pulmonary cells in acute lung injury: lessons from clinical practice","volume":"23","author":"Enomoto","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13045-022-01391-4","article-title":"Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance","volume":"15","author":"Fu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"749","DOI":"10.2169\/internalmedicine.3932-24","article-title":"Successful treatment with ramucirumab plus erlotinib following osimertinib-induced interstitial lung disease","volume":"64","author":"Fujimoto","year":"2025","journal-title":"Intern Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1200\/JCO.2010.33.4235","article-title":"Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin\/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)","volume":"29","author":"Fukuoka","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"102724","DOI":"10.1016\/j.ctrv.2024.102724","article-title":"Neoadjuvant EGFR-TKI therapy in non-small cell lung cancer","volume":"126","author":"Grant","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1410684","DOI":"10.3389\/fphar.2024.1410684","article-title":"Case report: EGFR-TKI rechallenge after osimertinib-induced interstitial lung disease: a case report and literature review","volume":"15","author":"Gu","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1200\/JCO.22.02186","article-title":"Adjuvant osimertinib for resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer: updated results from the phase III randomized ADAURA trial","volume":"41","author":"Herbst","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"823","DOI":"10.2169\/internalmedicine.3689-19","article-title":"Successful Re-administration of osimertinib in osimertinib-induced interstitial lung disease with an organizing pneumonia pattern: a case report and literature review","volume":"59","author":"Itano","year":"2020","journal-title":"Intern Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e24393","DOI":"10.1097\/MD.0000000000024393","article-title":"Almonertinib-induced interstitial lung disease: a case report","volume":"100","author":"Jiang","year":"2021","journal-title":"Med. Baltim."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1002\/art.42861","article-title":"American college of rheumatology (ACR)\/American college of chest physicians (CHEST) guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases","volume":"76","author":"Johnson","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s00408-023-00669-9","article-title":"Efficacy and safety of Re-administration of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) after EGFR-TKI-Induced interstitial lung disease (CS-Lung-005)","volume":"202","author":"Kanaji","year":"2024","journal-title":"Lung"},{"key":"B19","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2169\/internalmedicine.8947-17","article-title":"Successful osimertinib rechallenge with steroid therapy after osimertinib-induced interstitial lung disease","volume":"57","author":"Kiriu","year":"2018","journal-title":"Intern Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s10637-020-01005-1","article-title":"Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma","volume":"39","author":"Kodama","year":"2021","journal-title":"Invest New Drugs"},{"key":"B21","doi-asserted-by":"publisher","first-page":"103996","DOI":"10.1016\/j.esmoop.2024.103996","article-title":"Pan-asian adapted ESMO clinical Practice guidelines for the diagnosis, treatment and follow-up of patients with oncogene-addicted metastatic non-small-cell lung cancer","volume":"9","author":"Lee","year":"2024","journal-title":"ESMO Open"},{"key":"B22","doi-asserted-by":"publisher","first-page":"315","DOI":"10.21873\/invivo.11776","article-title":"Osimertinib in pulmonary manifestations: two case reports and review of the literature","volume":"34","author":"Lu","year":"2020","journal-title":"Vivo"},{"key":"B23","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.jtho.2021.10.024","article-title":"Efficacy of aumolertinib (HS-10296) in patients with advanced EGFR T790M+ NSCLC: updated post-national medical products administration approval results from the APOLLO registrational trial","volume":"17","author":"Lu","year":"","journal-title":"J. Thorac. Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"3162","DOI":"10.1200\/JCO.21.02641","article-title":"AENEAS: a randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastaticnon-small-cell lung cancer with EGFR exon 19 deletion or L858R mutations","volume":"40","author":"Lu","year":"","journal-title":"J. Clin. Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1001\/jama.2024.3669","article-title":"Interstitial lung disease: a review","volume":"331","author":"Maher","year":"2024","journal-title":"JAMA"},{"key":"B27","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s10637-017-0471-y","article-title":"Successful osimertinib rechallenge in a patient with advanced non-small cell lung cancer following osimertinib-induced interstitial lung disease after treatment with nivolumab","volume":"35","author":"Mamesaya","year":"2017","journal-title":"Invest New Drugs"},{"key":"B28","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1465-9921-13-39","article-title":"Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches","volume":"13","author":"Matsuno","year":"2012","journal-title":"Respir. Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1652750","DOI":"10.3389\/fphar.2025.1652750","article-title":"Risk of interstitial lung disease in non-small cell lung cancer treated with EGFR-TKI: a real-world pharmacovigilance study","volume":"16","author":"Miao","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1016\/j.jtho.2017.01.027","article-title":"Successful osimertinib rechallenge in a patient with T790M-Mutant non-small cell lung cancer after Osimertinib-Induced interstitial lung disease","volume":"12","author":"Miyauchi","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1159\/000516274","article-title":"Successful rechallenge with osimertinib after very acute onset of drug-induced pneumonitis","volume":"14","author":"Mohammed","year":"2021","journal-title":"Case Rep. Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1016\/j.cllc.2017.06.017","article-title":"Retreatment with osimertinib following pneumonitis","volume":"19","author":"Nagasaka","year":"2018","journal-title":"Clin. Lung Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1007\/s10637-020-00963-w","article-title":"Safety and efficacy of afatinib for the treatment of non-small-cell lung cancer following osimertinib-induced interstitial lung disease: a retrospective study","volume":"38","author":"Nasu","year":"2020","journal-title":"Invest New Drugs"},{"key":"B34","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2169\/internalmedicine.5435-20","article-title":"Successful treatment with afatinib after osimertinib-induced interstitial lung disease in a patient with EGFR-mutant non-small-cell lung cancer","volume":"60","author":"Nishima","year":"2021","journal-title":"Intern Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"792","DOI":"10.3390\/ijms22020792","article-title":"Molecular and clinical features of EGFR-TKI-Associated lung injury","volume":"22","author":"Ohmori","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"815","DOI":"10.2174\/1568026620666200303123102","article-title":"Review on epidermal growth factor receptor (EGFR) structure, signaling pathways, interactions, and recent updates of EGFR inhibitors","volume":"20","author":"Sabbah","year":"2020","journal-title":"Curr. Top. Med. Chem."},{"key":"B38","doi-asserted-by":"publisher","first-page":"101450","DOI":"10.1016\/j.rmcr.2021.101450","article-title":"Successful treatment with afatinib following the failure of osimertinib rechallenge with osimertinib-induced interstitial lung disease: a case report","volume":"33","author":"Sato","year":"2021","journal-title":"Respir. Med. Case Rep."},{"key":"B39","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.rmcr.2017.12.005","article-title":"Successful osimertinib rechallenge after osimertinib-induced pneumonitis in a patient with lung adenocarcinoma","volume":"23","author":"Satoh","year":"2017","journal-title":"Respir. Med. Case Rep."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1519849","DOI":"10.3389\/fphar.2025.1519849","article-title":"Adverse event profiles of EGFR-TKI: network meta-analysis and disproportionality analysis of the FAERS database","volume":"16","author":"Shi","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"717","DOI":"10.2147\/OTT.S475836","article-title":"Safety and efficacy of gefitinib administration after Osimertinib-Induced interstitial lung disease: a six-case series","volume":"17","author":"Shimbu","year":"2024","journal-title":"Onco Targets Ther."},{"key":"B42","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"B43","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"e118","DOI":"10.1016\/j.jtho.2017.03.022","article-title":"Osimertinib-induced interstitial lung disease presenting as eosinophilic pneumonia","volume":"12","author":"Tachi","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"17534666221117002","DOI":"10.1177\/17534666221117002","article-title":"Immunomodulatory treatment of interstitial lung disease","volume":"16","author":"van den Bosch","year":"2022","journal-title":"Ther. Adv. Respir. Dis."},{"key":"B46","doi-asserted-by":"publisher","first-page":"101766","DOI":"10.5306\/wjco.v16.i3.101766","article-title":"Furmonertinib re-challenge for epidermal growth factor receptor-mutant lung adenocarcinoma after osimertinib-induced interstitial lung disease: a case report","volume":"16","author":"Wei","year":"2025","journal-title":"World J. Clin. Oncol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12931-020-1296-3","article-title":"Progression of fibrosing interstitial lung disease","volume":"21","author":"Wong","year":"2020","journal-title":"Respir. Res."},{"key":"B48","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.jfma.2023.04.018","article-title":"Regulation of dendritic cell maturation in osimertinib-treated lung adenocarcinoma patients","volume":"122","author":"Wu","year":"2023","journal-title":"J. Formos. Med. Assoc."},{"key":"B49","doi-asserted-by":"publisher","first-page":"4021","DOI":"10.3390\/ijms20164021","article-title":"Blockade of EGFR activation promotes TNF-induced lung epithelial cell apoptosis and pulmonary injury","volume":"20","author":"Yamaoka","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B50","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.2169\/internalmedicine.4877-24","article-title":"Successful switch to afatinib and osimertinib rechallenge with corticosteroids after osimertinib-induced interstitial lung disease: a case report and literature review","volume":"64","author":"Yanai","year":"2025","journal-title":"Intern Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"19555","DOI":"10.1038\/s41598-022-23834-1","article-title":"A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for osimertinib","volume":"12","author":"Yin","year":"2022","journal-title":"Sci. Rep."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1785616\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T07:49:38Z","timestamp":1776066578000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1785616\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":51,"alternative-id":["10.3389\/fphar.2026.1785616"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1785616","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"article-number":"1785616"}}